



Wednesday December 4, 2024

4:30 PM Paris time

Session 3 - Chairs: Bart Staels, Amalia Gastaldelli (Hybrid session)

Abstracts - New pharmacological strategies for MASH

- Phase 3 ESSENCE Trial: Semaglutide in metabolic dysfunction-associated steatohepatitis - *Cyrielle Caussy*
- Pharmacological inhibition of fructose metabolism reduces liver fat and improves insulin sensitivity in participants with MASLD - *Evi J.C. Koene*
- Beyond GLP-1, managing cirrhosis and complications in patients with advanced MASH - *Phil Ambery*
- Comparative effect estimates of tirzepatide, semaglutide and liraglutide in risk reduction of major adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease - *Alex Henney*

Invited Lectures: MASLD Guidelines and Non-invasive Tests

- Update on new EASL-EASD-EASO guidelines for MASLD. *Sven Francque* (UZA, Antwerp, Belgium) 25 min
- Non-invasive tests for MASLD screening. *Laurent Castera* (Paris, France) 25 min
- *Round table with panel discussion*

Thursday December 5, 2024

4:45 PM Paris time **Session 9 - (Hybrid session) - Chairs: Patrick Schrauwen, Ulf Riserus**

Abstracts - Adipose tissue: Metabolic and Cellular Adaptations in Obesity and Dietary Interventions

- Peripheral insulin sensitivity is lower after 4-week high-fructose compared to 4-week high-saturated fat consumption in overweight individuals - *Kay HM Roumans*
- Obesity and weight loss change differently the metabolomic profile of white and brown adipose tissue - *Lia De Benedictis*
- Metabolic adaptations of resident macrophages in the physiopathological context of MASLD - *Razafiarison Joanna*

Invited Lectures: Adipose Tissue and Lipotoxicity

- Adipose tissue adaptation in obesity. *Michael Ryden* (Stockholm Sweden) 25min
- Adipose tissue-liver cross-talk. *Delphine Eberlé* (Lille, France) 25 min
- *Round table with panel discussion*